CRYOPORT, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
CRYOPORT, INC. (CYRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $5.15 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-06
- CRYOPORT, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $4.82, a 16.14% increase year-over-year.
- CRYOPORT, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $4.15, a 52.41% decline year-over-year.
- CRYOPORT, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $8.72, a 31.07% decline year-over-year.
- CRYOPORT, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $12.65, a 31.44% decline year-over-year.
- CRYOPORT, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2013 was $0.26, a 79.03% decline from fiscal 2012.
- CRYOPORT, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2012 was $1.24.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.15 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $4.82 10-Q · filed 2026-05-05 | |||
| 2025-09-30 | $4.13 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $4.08 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $4.15 10-Q · filed 2025-05-08 | |||
| 2024-09-30 | $7.67 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $7.81 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $8.72 10-Q · filed 2024-05-08 | |||
| 2023-09-30 | $12.03 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $12.65 10-Q · filed 2023-08-09 | |||
| 2023-03-31 | $12.65 10-Q · filed 2023-05-04 | |||
| 2022-09-30 | $17.34 10-Q · filed 2022-11-04 | |||
| 2022-06-30 | $17.30 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $18.45 10-Q · filed 2022-05-05 | |||
| 2018-12-31 | $8.86 10-Q · filed 2019-08-09 | |||
| 2014-09-30 | $0.39 10-Q · filed 2014-11-12 | |||
| 2014-06-30 | $0.42 10-Q · filed 2014-07-31 | |||
| 2013-12-31 | $0.24 10-Q · filed 2014-02-13 | |||
| 2013-09-30 | $0.24 10-Q · filed 2013-11-18 | |||
| 2013-06-30 | $0.24 10-Q · filed 2013-08-14 | |||
| 2013-03-31 | $0.26 10-K · filed 2013-06-25 | |||
| 2012-12-31 | $0.25 10-Q · filed 2014-02-13 | |||
| 2012-09-30 | $0.39 10-Q · filed 2013-11-18 | |||
| 2012-06-30 | $0.47 10-Q · filed 2013-08-14 | |||
| 2012-03-31 | $1.24 10-K · filed 2013-06-25 | |||
| 2011-12-31 | $1.24 10-Q · filed 2013-02-14 | |||
| 2011-09-30 | $1.25 10-Q · filed 2012-11-09 | |||
| 2011-06-30 | $1.27 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |